Intra-Cellular Therapies, Inc. (ITI) Company Profile

03:45 EDT 22nd September 2018 | BioPortfolio

Intra-Cellular Therapies, Inc. (ITI) is a biotechnology company developing novel therapeutics for the treatment of depression, schizophrenia, Alzheimer's and Parkinson's disease and other disorders of the Central Nervous System. Using IntraPath, its broad technology platform, ITI has identified nerve-signaling proteins, validated their roles in vivo and is currently using these proteins as targets for small molecule drugs. Commercializing the Nobel-prize winning research of Dr. Paul Greengard, ITI is uniquely positioned to develop novel therapies for neuropsychiatric and neurodegenerative disorders. With its broad expertise in the molecular basis of neurotransmitter and drug action, ITI is validating drug candidates for its internal drug discovery programs and for its pharmaceutical partners. Founded by Drs. Greengard, Sharon Mates and Allen Fienberg, ITI began operations in May 2002 and is headquartered in the Audubon Biomedical Science & Technology Park in New York City.


3960 Broadway
New York
New York
United States of America


Phone: 212.923.3344
Fax: 212.923.3388

News Articles [604 Associated News Articles listed on BioPortfolio]

Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia

NEW YORK, June 06, 2018 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disord...

Intra-Cellular gets positive FDA feedback on rolling NDA for schizophrenia drug

The FDA and Intra-Cellular Therapies have reached an agreement on the proposed content and timing of a rolling new drug appli -More- 

Intra-Cellular Therapies' (ITCI) CEO Sharon Mates on Q2 2018 Results - Earnings Call Transcript

Management tracks: Athenex, Intra-Cellular

3 Things In Biotech, May 7: Novartis Thyroid Breakout, Redhill's Stomach Bugs, Intra-Cellular Update On Schizoid Drugs

Cellular valve structure opens up potential novel therapies

(University of Zurich) Biochemists at the University of Zurich have determined the detailed structure of a volume-regulated chloride channel. This cellular valve is activated in response to swelling t...

Gene Therapies are Proving their Worth, but with Million Dollar Price Tags, it’s not Clear Who should Pay for Them

Sterghios Moschos, Associate Professor in Cellular and Molecular Sciences at Northumbria University discusses the benefits of gene therapies and the financial implications of treatments. If you were b...

Younger age, worse knee pain predicts benefit from hyaluronic acid injection in OA

Worse levels of knee pain, younger age and less severe structural damage are reliable predictors of which patients with osteoarthritis would benefit most from intra-articular hyaluronic acid injection...

PubMed Articles [2413 Associated PubMed Articles listed on BioPortfolio]

"Yoga resets my inner peace barometer": A qualitative study illuminating the pathways of how yoga impacts one's relationship to oneself and to others.

The purpose of this qualitative study was twofold: (1) to better understand how yoga practitioners perceive intra- and interpersonal outcomes of their yoga practice, and (2) to develop a conceptual mo...

Intra-articular 2.5% polyacrylamide hydrogel for the treatment of knee osteoarthritis: an observational proof-of-concept cohort study.

There is a drought of effective treatments of knee osteoarthritis (OA) and new therapies are needed. The present study has been conducted to establish an initial estimate of effectiveness of intra-art...

Endothelial cell regulation through epigenetic mechanisms: depicting parallels and its clinical application within an intra-islet microenvironment.

The intra-islet endothelial cells (ECs), the building blocks of islet microvasculature, govern a number of cellular and pathophysiological processes associated with the pancreatic tissue. These cells ...

Clinical Relevance of Intra-Tumour Heterogeneity.

Fairness in Manufacturing Cellular Therapies.

Clinical Trials [3588 Associated Clinical Trials listed on BioPortfolio]

Regenerative Cellular Therapies, Physiology, Pathology and Developmental Biology

This study aims to use tissue from deceased organ donors to investigate organ physiology, developmental biology, as well as the development of future regenerative cellular therapies. It wi...

Cellular Adoptive Immunotherapy in Treating Patients With Glioblastoma Multiforme

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, may stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may stimulate the...

Cellular Adoptive Immunotherapy in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer

RATIONALE: Biological therapies, such as cellular adoptive immunotherapy, stimulate the immune system in different ways and stop tumor cells from growing. PURPOSE: This phase I trial is s...

Impact of Omega-3 Fatty Acids on Lactate

Pre- and intra-operative nutritional support in patient undergoing major surgery results in decreased morbidity and mortality. Studies investigating the role of omega-3 fatty acids in thes...

Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)

Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is designed to perform a personalized clinical trial by first analyzing the expression of tumor assoc...

Companies [1215 Associated Companies listed on BioPortfolio]

Intra-Cellular Therapies, Inc.

Intra-Cellular Therapies, Inc. (ITI)

Intra-Cellular Therapies, Inc. (ITI) is a biotechnology company developing novel therapeutics for the treatment of depression, schizophrenia, Alzheimer's and Parkinson's disease and other disorders of...


Philadelphia-based Intracorp, a subsidiary of CIGNA Corporation, helps employers maximize their workers' compensation and disability benefits programs to enhance the well-being an...

Intra-Lock® International, Inc.

Intra-Lock® International Inc., headquartered in Boca Raton, Florida, USA, is a leading provider of innovative dental restoration solutions including a wide range of dental imp...

Aastrom Biosciences, Inc.

Founded in 1989 and with headquarters in Ann Arbor, Michigan, Aastrom Biosciences is dedicated to the development of stem cell treatments for critical cardiovascular diseases. Aastrom is currently e...

More Information about "Intra-Cellular Therapies, Inc. (ITI)" on BioPortfolio

We have published hundreds of Intra-Cellular Therapies, Inc. (ITI) news stories on BioPortfolio along with dozens of Intra-Cellular Therapies, Inc. (ITI) Clinical Trials and PubMed Articles about Intra-Cellular Therapies, Inc. (ITI) for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Intra-Cellular Therapies, Inc. (ITI) Companies in our database. You can also find out about relevant Intra-Cellular Therapies, Inc. (ITI) Drugs and Medications on this site too.

Quick Search


Relevant Topics

Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...

Bipolar Disorders
Bipolar disorder, also known as manic-depressive illness, is a brain disorder that causes unusual shifts in mood, energy, activity levels, and the ability to carry out day-to-day tasks. Over half of Bipolar cases develops before the age of 25. Bipolar ...

Corporate Database Quicklinks

Searches Linking to this Company Record